Immutep Announced Earlier It Was Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Portfolio Pulse from Charles Gross
Immutep Limited (NASDAQ: IMMP) has been granted a new US patent (number 11,680,104) for its pre-clinical immunosuppressive product candidate IMP761, a first-in-class agonist LAG-3 antibody designed to target the root cause of autoimmune diseases.
June 20, 2023 | 8:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited has been granted a US patent for its pre-clinical immunosuppressive product candidate IMP761, potentially boosting its stock price.
The grant of a new US patent for Immutep's product candidate IMP761 is a significant milestone for the company, as it provides intellectual property protection and validates the novelty of the product. This news is likely to have a positive impact on the company's stock price in the short term, as it demonstrates progress in the development of its immunosuppressive product pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100